Oncodesign Precision Medicine (STU:ZR8) Risk Assessment

View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Oncodesign Precision Medicine is: No Data: Cannot be evaluated.

Competitive Comparison of Oncodesign Precision Medicine's Risk Assessment

For the Biotechnology subindustry, Oncodesign Precision Medicine's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncodesign Precision Medicine's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's Risk Assessment falls into.

Oncodesign Precision Medicine (STU:ZR8) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Oncodesign Precision Medicine Risk Assessment Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncodesign Precision Medicine (STU:ZR8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (STU:ZR8) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 rue Jean Mazen, Dijon, FRA, 21000

Website

https://www.opm.oncodesign.com

Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (STU:ZR8) Headlines

No Headlines